Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Shareholders to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESS Newswire / February 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential ...
Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Shareholders to Connect
NEW YORK CITY, NY / ACCESS Newswire / February 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential ...
Brokerages Set Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Price Target at $7.33
Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Get Free Report) have received an average recommendation of “Moderate Buy” from the nine ratings firms that are covering the firm, Marketbeat.com ...
HDAC Inhibitor Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies by DelveInsight
DelveInsight’s, “HDAC Inhibitor Pipeline Insight” report provides comprehensive insights about 40+ companies and 50+ pipeline ...
Amylyx Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
A live webcast of the presentation can be accessed under "Events and Presentations" in the Investor section of the Company’s website, https://investors.amylyx.com/events-presentations, and will be ...